AZmed vs Milvue (2026)
Both read plain radiographs across trauma and chest, both are FDA cleared and assistive, both grade A on AI centrality, so the split is evidence quality against product breadth and deployment flexibility. If the strongest, most independently validated fracture evidence is what you want, start with AZmed, which grades A on clinical evidence on externally generated multi country studies. If you want detection plus automatic measurements and a pre filled report in one tool, with an explicit on premise option, start with Milvue, accepting thinner and less broken out performance reporting. AZmed concentrates on detection with disciplined reporting. Milvue adds roughly 60 automatic measurements and names precisely which product carries which authorization in which market.
- Stronger, more independent evidence: clinical evidence A on externally generated studies at University Hospitals Cleveland and SimonMed and a 258,373 X-ray analysis across 26 countries, against Milvue's clearance reader study and single peer reviewed emergency paper.
- More disciplined performance reporting: AZmed publishes per study sensitivity and specificity, where Milvue reports an aggregate area under the curve above 96 percent not broken out by pathology, region, or age.
- Better documented generalization: its published validation spans more sites and countries, earning a higher governance grade.
- Detection plus measurement in one tool: roughly 60 automatic measurements across legs, hip, pelvis, foot, shoulder, spine, knee, and bone age alongside fracture and chest detection, where most competitors do one or the other.
- An explicit on premise option: the suite runs via secure cloud or on premises, which matters for institutions unwilling to send imaging outside their perimeter and which few competitors state plainly.
- Unusually precise regulatory disclosure: it names which product carries which authorization in which market rather than claiming blanket clearance, and labels its report generation module as non device software, separating the regulated detection engine from the reporting layer.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. AZmed and Milvue are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | AZmed | Milvue |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2018 | 2018 |
| Headquarters | Paris, France | Grenoble, France |
| Website | azmed.co | milvue.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards AZmed its top capability grade on AI Centrality, Clinical and Operational Evidence and FDA and Regulatory Status. Set against Milvue, AZmed grades higher on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and AI Governance and Bias Disclosure. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
The AI Health Index awards Milvue its top capability grade on AI Centrality and FDA and Regulatory Status. Set against AZmed, Milvue grades higher on Deployment Model and Data Residency. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, July 2026
Questions buyers ask
Should we choose AZmed or Milvue?
On the axes where the AI Health Index separates them, AZmed grades higher on several axes, including Model and Technology Transparency, Clinical and Operational Evidence and AI Governance and Bias Disclosure, and Milvue grades higher on Deployment Model and Data Residency. AZmed leads on the greater share of scored axes, but the split means the decision turns on which constraint is binding rather than on an overall winner.
Where do AZmed and Milvue differ most?
The widest separation the AI Health Index records between AZmed and Milvue is on Model and Technology Transparency, where AZmed grades B and Milvue grades C. That axis sits in the AI Capability group, so it should carry the most weight for a buyer whose binding constraint is how much of the work the model itself is trusted to do.
Where do AZmed and Milvue grade the same?
The AI Health Index grades AZmed and Milvue the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model Supply Chain Disclosure. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
Both are plain radiograph detection tools spanning trauma and chest, both FDA cleared and assistive, and both are French vendors selling into the US without a published security attestation or business associate commitment, so a buyer should confirm processing location and terms.
Milvue's model transparency is the weaker of the two: its headline area under the curve above 96 percent is not broken out by pathology, region, or patient age, and its claim to be first in adult and pediatric fractures is not substantiated against any named comparator or benchmark. Neither publishes pricing. Both carry multiple modules with different regulatory status, so a buyer should establish exactly which detection, measurement, or reporting components a license covers.